On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

TNI BioTech Inc. (TNIB) Able to Target Numerous Fatal Diseases with Immunology Approach

TNI BioTech aims for world leadership in the area of immunology. It plans to fight infectious diseases by using Methionine Enkephalin (MENK), a human hormone produced naturally by the human immune system. It is believed that MENK is toxic to tumor cells but does not hurt the human body. TNIB’s most advanced clinical programs involve immunotherapy that works by isolating a patient’s lymphocytes and then incubating them together with an enriching external incubation system. After incubation, the patient’s lymphocytes are reinfused back into the patient where they combat and destroy tumor cells.

Although TNIB considers any condition that results in altered-immune response a target for investigation, the company will most likely focus its efforts on using MENK in the treatment of 5 major types of illnesses: 1) Autoimmune states such as rheumatoid arthritis and multiple sclerosis; 2) As an adjunct to antibiotics in the treatment of infectious diseases; 3) In cancer patients undergoing chemotherapy, radiation treatments, or surgery; 4) Patients with AIDS, in combination with retroviral drug therapy; and 5) In wound healing or herpes viral infections.

To further its goal of prominence in the field of immunology, the company recently acquired certain technology developed by Dr. Bernard Bihari, a well-known AIDS researcher. The portfolio portfolio contains six patents and applications related to:
• Cancer of the prostate, lymphoproliferative syndrome, including such diseases as malignant lymphoma, chronic lymphocytic leukaemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma;
• Infectious diseases such as chronic herpes virus infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, chronic infections due to the Epstein-Barr virus, and chronic inflammatory conditions including chronic fatigue syndrome; and
• A treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC).

Dr. Bernard Bihari was the discoverer of the clinical effects of Low Dose Naltrexone (LDN) in humans. In his groundbreaking clinical trial of patients with HIV/AIDS at Downstate Medical Center in 1985-86, Dr. Bihari discovered the significant effectiveness of LDN in protecting the battered immune systems of those who were infected. Equipped with the clinical trial knowledge, he entered private practice in an attempt to counter the then untreatable disease by using LDN – and did so in some cases dramatically. TNIB intends to continue Dr. Bihari’s work on the use of LDN by conducting Phase III trials.

Asked for comment on the purchase of Dr. Bihari’s technology, Dr. Nicholas Plotnikoff, Chairman of TNI BioTech, Inc., said, “I worked with Dr. Bernard Bihari for many years and I believe acquiring all of the technology of Dr. Bihari will allow the company, we hope, to move forward to phase III clinical trials in both the United States and Africa within the next 12 months. In our opinion, LDN holds great promise for the millions of people worldwide with autoimmune diseases or central nervous system disorders or who face a deadly cancer. It could prove to be the first low-cost, easy to administer, and side-effect-free therapy for Cancer, HIV/AIDS, MS and Crohn’s disease.”

Another major step forward for the company was Dr. Ronald Herberman joining the company as Senior Vice President of Research and Development and Chief Medical Officer. Dr. Herberman’s responsibilities include leading the company’s global development, clinical research, and medical initiatives.

Dr. Herberman is widely recognized as a top researcher in the field of immunology. He has received many awards, including the Lifetime Science Award from the Institute for Advanced Studies in Immunology and Aging. During the period of 1981 to 1990, Dr. Herberman was recognized as one of the 100 most-cited research authors in the immunology area.

Dr. Nicholas Plotnikoff, TNI BioTech, Inc. Chairman, noted that the company’s hiring of Dr. Herberman reflects TNI BioTech’s highest priority: to become a world-class leader in groundbreaking therapeutics for patients who are afflicted with cancer, autoimmune, and infectious disease, including HIV/AIDS.

“In order to successfully become a world-class leader,” stated Dr. Plotnikoff, “we need significant expertise in clinical, regulatory and leadership development, along with a deep knowledge of immunology and Dr. Herberman brings demonstrated strengths in these areas having made major discoveries in his field and has fostered the application of this information to novel approaches to cancer therapy, diagnosis and prevention during his time as a leader at the National Cancer Institute and Founding Director of the University of Pittsburgh Cancer Institute.”

Dr. Plotnikoff added, “During his career, Dr. Herberman has been recognized as a leader in the field of immunology. The phenomenon of natural killer (NK) cell-mediated cytotoxicity against tumors was first discovered in Dr. Herberman’s laboratory at the National Cancer Institute in the early 1970s. In addition to his pioneering investigation of NK cells, Dr. Herberman has played a leading role in multiple areas of tumor immunology. TNI BioTech therapies and treatments draw upon the theory that medicine can enlist the body’s own immune system to combat cancer and autoimmune diseases that are Dr. Herberman’s specialty. His experience and strategic perspective precisely meet TNI BioTech’s needs today.”

Dr. Herberman commented: “I am very excited to assume a leadership position in TNI Biotech Inc. I have had the privilege to know Dr. Plotnikoff for about 30 years and I have been very impressed with his pioneering studies of the effects of opioid peptides on the immune system. I am convinced that TNI Biotech’s drugs have much potential for the treatment of not only cancer, but also a range of other diseases including multiple sclerosis, HIV/AIDS, and Crohn’s Disease. I intend to rapidly build on a pre-existing foundation of clinical research with low dose naltrexone and MENK, and develop innovative approaches to use them to stimulate the immune system to make an impact on these and other chronic diseases.”

In addition to his other duties, Dr. Herberman will be a member of the company’s executive leadership team. He will report to Dr. Eugene Youkilis, President and the Board of Directors. As the company’s Chief Medical Officer, Dr. Herberman will employee his extensive experience in all phases of drug development and drug portfolio management — including acquisition of new assets and relationships with regulators and government agencies. Dr. Herberman will also retain specific accountabilities relating to patient safety.

To learn more about the company and its immunotherapy technologies, visit www.tnibiotech.com

Let us hear your thoughts: TNI BioTech, Inc. Message Board

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered